Literature DB >> 2569345

Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists.

G Hanft1, G Gross.   

Abstract

1. The affinities of urapidil derivatives and other antagonists for alpha 1-adrenoceptors labelled by [3H]-prazosin were determined on membranes of six different rat tissues. 2. Urapidil and its 5-acetyl-, 5-formyl- and 5-methyl-derivative displaced [3H]-prazosin from alpha 1-adrenoceptor binding sites in a concentration-dependent manner which varied with tissue. IC50 values were lower in vas deferens, hippocampus and cerebral cortex than in heart, liver and spleen. For 5-methyl-urapidil, binding to two distinct sites could be demonstrated with mean K1 values of about 0.6 and 45 nM. Saturation binding studies with [3H]-prazosin in the presence of 5-methyl-urapidil indicated a competitive type of interaction between 5-methyl-urapidil and [3H]-prazosin. 3. The proportion of [3H]-prazosin binding sites with high affinity for 5-methyl-urapidil was 58% in vas deferens, 69% in hippocampus, 41% in cerebral cortex and 23% in myocardium. In liver and spleen virtually no high affinity sites were found. These values were in good agreement with the percentages of binding sites with high affinities for WB-4101 and phentolamine, indicating that all these antagonists bind to the same subtype of alpha 1-recognition sites, whereas other alpha-antagonists like BE 2254, yohimbine and unlabelled prazosin did not discriminate between two binding sites. 4. Preincubating membranes of the cerebral cortex with chloroethylclonidine preferentially inactivated [3H]-prazosin binding sites with low affinity for 5-methyl-urapidil. 5. The antagonist potencies of 5-methyl-urapidil and WB-4101 against alpha 1- adrenoceptor-mediated contractile responses were higher in vas deferens than in myocardium. The alpha 1-mediated effects in vas deferens but not in the heart were highly susceptible to nitrendipine. 6. Using 5-methyl-urapidil, the existence of two distinct alpha 1-adrenoceptor recognition sites could be demonstrated which correspond to the proposed alpha 1A- and alpha 1B-subtypes. Since 5-methyl-urapidil is one of the ligands with most selectivity between these subtypes in binding studies it may serve as a valuable tool for such investigations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569345      PMCID: PMC1854578          DOI: 10.1111/j.1476-5381.1989.tb12005.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  Identification of subtypes of [3H]prazosin-labelled alpha 1 receptor binding sites in rat brain.

Authors:  A L Morrow; G Battaglia; A B Norman; I Creese
Journal:  Eur J Pharmacol       Date:  1985-02-26       Impact factor: 4.432

2.  Adrenergic regulation of gluconeogenesis: possible involvement of two mechanisms of signal transduction in alpha 1-adrenergic action.

Authors:  J A García-Sáinz; S M Hernández-Sotomayor
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

Review 3.  Evidence for and against heterogeneity of alpha 1-adrenoceptors.

Authors:  J P Hieble; R M DeMarinis; W D Matthews
Journal:  Life Sci       Date:  1986-04-14       Impact factor: 5.037

4.  A practical computer-based approach to the analysis of radioligand binding experiments.

Authors:  G A McPherson
Journal:  Comput Programs Biomed       Date:  1983 Aug-Oct

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding.

Authors:  A L Morrow; I Creese
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

7.  Cardiovascular effects and interaction with adrenoceptors of urapidil.

Authors:  P A van Zwieten; A de Jonge; B Wilffert; P B Timmermans; J J Beckeringh; M J Thoolen
Journal:  Arch Int Pharmacodyn Ther       Date:  1985-08

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Effects of urapidil, clonidine, prazosin and propranolol on autonomic nerve activity, blood pressure and heart rate in anaesthetized rats and cats.

Authors:  K H Sanders; I Jurna
Journal:  Eur J Pharmacol       Date:  1985-04-02       Impact factor: 4.432

10.  Thyroid-dependent alterations of myocardial adrenoceptors and adrenoceptor-mediated responses in the rat.

Authors:  G Gross; I Lues
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-06       Impact factor: 3.000

View more
  53 in total

1.  Investigation of the subtypes of alpha1-adrenoceptor mediating contractions of rat vas deferens.

Authors:  V Honner; J R Docherty
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

2.  Sustained increase in rat myocardial alpha 1A-adrenoceptors induced by 6-hydroxydopamine treatment involves a decelerated receptor turnover.

Authors:  J Sallés; S Gascón; A Badia
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-03       Impact factor: 3.000

3.  Differences between full and partial alpha-adrenoceptor agonists in eliciting phasic and tonic types of responses in the longitudinal smooth muscle of the rat portal vein.

Authors:  H R Schwietert; D Wilhelm; B Wilffert; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-08       Impact factor: 3.000

4.  Identification of the alpha1L-adrenoceptor in rat cerebral cortex and possible relationship between alpha1L- and alpha1A-adrenoceptors.

Authors:  S Morishima; F Suzuki; H Yoshiki; A S Md Anisuzzaman; Z S Sathi; T Tanaka; I Muramatsu
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

5.  Study of the mechanism of the relaxant action of (+)-glaucine in rat vas deferens.

Authors:  F Orallo; A Fernández Alzueta; M I Loza; N Vivas; A Badía; M Campos; M A Honrubia; M I Cadavid
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

Review 6.  Classification of alpha 1-adrenoceptor subtypes.

Authors:  M C Michel; B Kenny; D A Schwinn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-07       Impact factor: 3.000

7.  Characterization of alpha 1-adrenoceptor subtypes in tension response of human prostate to electrical field stimulation.

Authors:  J H Guh; S C Chueh; F N Ko; C M Teng
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

8.  Alpha(1D)-adrenergic receptor insensitivity is associated with alterations in its expression and distribution in cultured vascular myocytes.

Authors:  Lin-lin Fan; Shuang Ren; Hong Zhou; Ying Wang; Ping-xiang Xu; Jun-qi He; Da-li Luo
Journal:  Acta Pharmacol Sin       Date:  2009-12       Impact factor: 6.150

9.  Relation between alpha 1-adrenoceptor subtypes and noradrenaline-induced contraction in rat portal vein smooth muscle.

Authors:  I Sayet; G Neuilly; L Rakotoarisoa; C Mironneau; J Mironneau
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

10.  Comparison of guinea-pig, bovine and rat alpha 1-adrenoceptor subtypes.

Authors:  R Büscher; C Heeks; K Taguchi; M C Michel
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.